NewAmsterdam Pharma Company N.V. financial statements, including revenue, expenses, profit, and loss
The total revenue of NAMS for the last quarter is 29.11 M USD, and it's 1177.36% higher compared to the previous quarter. The net income of Q3 24 is -16.65 M USD.